Sagimet Biosciences Inc. Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions
Sagimet Biosciences Inc. (SGMT) reported Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions of $306.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-11.
Financial Statements › Notes › Income Taxes › Income Tax Uncertainties
us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions · last filed 2026-03-11
- Sagimet Biosciences Inc. unrecognized tax benefits, increase resulting from current period tax positions for fiscal 2025 was $306.00K, a 53.14% decline from fiscal 2024.
- Sagimet Biosciences Inc. unrecognized tax benefits, increase resulting from current period tax positions for fiscal 2024 was $653.00K, a 161.20% increase from fiscal 2023.
- Sagimet Biosciences Inc. unrecognized tax benefits, increase resulting from current period tax positions for fiscal 2023 was $250.00K, a 49.90% decline from fiscal 2022.
- Sagimet Biosciences Inc. unrecognized tax benefits, increase resulting from current period tax positions for fiscal 2022 was $499.00K.
| Period end | Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions 12 month |
|---|---|
| 2025-12-31 | $306.00K 10-K · filed 2026-03-11 |
| 2024-12-31 | $653.00K 10-K · filed 2026-03-11 |
| 2023-12-31 | $250.00K 10-K · filed 2025-03-12 |
| 2022-12-31 | $499.00K 10-K · filed 2024-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |